Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
This is an old revision of this page, as edited by 2.227.60.240 (talk) at 22:45, 9 January 2012 (→Adverse effects: that source did NOT say anything that the[REDACTED] page claimed. check it yourself, those statements are unfounded). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
The NIH states that yohimbine hydrochloride is the standardized form of yohimbine that is available as a prescription medicine in the United States, and has been shown in human studies to be effective in the treatment of male impotence.
Yohimbine Hydrochloride, USP—a standardized form of yohimbine—is a prescription medicine that has been used to treat erectile dysfunction. Controlled studies suggest that it is not always an effective treatment for impotence, and evidence of increased sex drive (libido) is anecdotal only.
It cannot be excluded that orally administered yohimbine can have a beneficial effect in some patients with ED. The conflicting results available may be attributed to differences in drug design, patient selection, and definitions of positive response. However, generally, available results of treatment are not impressive.
Yohimbine blocks the pre- and post-synaptic alpha-2 adrenoceptors. Blockade of post-synaptic alpha-2 adrenoceptors leads to minor corpora cavernosa smooth muscle relaxation. In fact the majority of adrenoceptors in the corpora cavernosa are alpha-1. Blockade of pre-synaptic alpha-2 adrenoceptors leads to increased release of neurotransmitters in the Central Nervous System and in the corpora cavernosa penis such as nitric oxide, noradrenaline and dopamine. Whether Nitric Oxide released in the corpora cavernosa has a relaxing effect, noradrenaline has a much powerful constricting effect by stimulating the unblocked alpha-1 adrenoceptors. Concomitant use of an alpha-1 blocking agent will prevent constriction caused by the increased adrenergic stimulation.
Pausinystalia Yohimbe (Yohimbe) doesn't contain just Yohimbine. It contains around 55 other alkaloids and Yohimbine accounts for 1% to 20% of total alkaloids. Among them Corynanthine is an alpha-1 adrenoceptor blocker. Hence the use of Yohimbe extract in sufficient dosages may provide concomitant alpha-1 and alpha-2 adrenoceptors blockade and thus may better enhance erections than Yohimbine alone.
Yohimbine has been shown to be effective in the reversal of sexual satiety and exhaustion in male rats. Yohimbine has also been shown to increase the volume of ejaculated semen in dogs, with the effect lasting at least five hours after administration. Yohimbine has been shown to be effective in the treatment of orgasmic dysfunction in men.
Fat loss
According to one study, oral yohimbine supplementation may actuate significant fat loss in athletes. Numerous bodybuilding supplement companies sell formulations of yohimbine for transdermal delivery to effect a local reduction of adipose tissue, although the experimental evidence for its efficiency is limited.
The addition of yohimbine to fluoxetine or venlafaxine has also been found to potentiate the antidepressant action of both of these agents.
Yohimbine has been used to facilitate recall of traumatic memories in the treatment of post traumatic stress disorder (PTSD). Use of yohimbine outside therapeutic settings may not be appropriate for persons suffering from PTSD.
In pharmacology, yohimbine is used as a probe for α2-adrenoceptor.
In veterinary medicine, yohimbine is used to reverse anesthesia from the drug xylazine in small and large animals.
Yohimbine is the principal alkaloid of the bark of the West African evergreen Pausinystalia yohimbe (formerly Corynanthe yohimbe), family Rubiaceae (Madder family). There are 31 other yohimbane alkaloids found in Yohimbe. In Africa, yohimbe has traditionally been used as an aphrodisiac. However, it is very important to note that while the terms yohimbine, yohimbine hydrochloride, and yohimbe bark extract are related, they are not interchangeable.
The main active chemical present in yohimbe bark is yohimbine HCl (indole alkaloid), found in the bark of the Pausinystalia yohimbe tree.
However, the levels of yohimbine that are present in yohimbe bark extract are variable and often very low. Therefore, although yohimbe bark has been used traditionally to reduce male erectile dysfunction, there is not enough scientific evidence to form a definitive conclusion in this area.
The tree is currently threatened with extinction in its native habitat due to international demand. Its conservation is difficult because the bioactivity of the tree has led many Western governments to declare it a proscribed species.
The therapeutic index of yohimbine is quite low; the range between an effective dose and a dangerous dose is very narrow. This may also lead to precipitation of panic disorder type reactions.
Yohimbine in combination with modafinil is frequently associated with nausea, dangerous acute rapid heart beat, and acute increased blood pressure. Yohimbine exhibits some degree of MAOI activity while modafinil has been shown to increase levels of various monamines, and therefore could result in severe risk of dangerous side effects.
Andersson, Karl-Erik; Steers, William D. (1998). "The pharmacological basis of sexual therapeutics". In Morales, Alvaro (ed.). Erectile dysfunction: issues in current pharmacotherapy. London: Martin Dunitz. pp. 97–124 . ISBN978-1-85317-577-0. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
^ Saenz De Tejada, I; Kim, NN; Goldstein, I; Traish, AM (2000). "Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum". International journal of impotence research. 12 Suppl 1: S20–25. PMID10845761.
Fernández-Guasti A, Rodríguez-Manzo G (2003). "Pharmacological and physiological aspects of sexual exhaustion in male rats". Scandinavian Journal of Psychology. 44 (3): 257–63. doi:10.1111/1467-9450.00343. PMID12914589. {{cite journal}}: Unknown parameter |month= ignored (help)
Yonezawa A, Yoshizumii M, Ebiko M, Amano T, Kimura Y, Sakurada S (2005). "Long-lasting effects of yohimbine on the ejaculatory function in male dogs". Biomedical Research. 26 (5): 201–6. doi:10.2220/biomedres.26.201. PMID16295696. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Adeniyi AA, Brindley GS, Pryor JP, Ralph DJ (2007). "Yohimbine in the treatment of orgasmic dysfunction". Asian Journal of Andrology. 9 (3): 403–7. doi:10.1111/J.1745-7262.2007.00276.x. PMID17486282. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Ostojic SM (2006). "Yohimbine: the effects on body composition and exercise performance in soccer players". Research in Sports Medicine. 14 (4): 289–99. doi:10.1080/15438620600987106. PMID17214405.
Dhir, A; Kulkarni, SK (2007). "Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test". Pharmacology. 80 (4): 239–43. doi:10.1159/000104877. PMID17622775.
van der Kolk, Bessel A. (1995). "The Treatment of Post Traumatic Stress Disorder". In Hobfoll, Stevan E.; De Vries, Marten W. (eds.). Extreme stress and communities: impact and intervention. Boston: Kluwer Academic Publishers. pp. 421–44. ISBN978-0-7923-3468-2. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
Morgan CA; Grillon C; Southwick SM; et al. (1995). "Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder". Psychopharmacology. 117 (4): 466–71. doi:10.1007/BF02246220. PMID7604149. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
^ Millan MJ; Newman-Tancredi A; Audinot V; et al. (2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse. 35 (2): 79–95. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. PMID10611634. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help); replacement character in |first5= at position 5 (help); replacement character in |last7= at position 4 (help)
Arthur JM, Casañas SJ, Raymond JR (1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors". Biochemical Pharmacology. 45 (11): 2337–41. doi:10.1016/0006-2952(93)90208-E. PMID8517875. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Kaumann AJ (1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149–54. doi:10.1007/BF00634263. PMID6136920. {{cite journal}}: Unknown parameter |month= ignored (help)
